Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 19Terminated 4Withdrawn 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Thymoma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Osteosarcoma 1Colonic Neoplasms 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Interventional × saracatinib × Clear all
NCT00752206 2020-01-18

A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

Sarcoma Alliance for Research through Collaboration

Phase 2 Terminated
38 enrolled 10 charts
Sarcoma

Recurrence, Osteosarcoma

NCT00397878 2019-08-20

AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
10 enrolled 7 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT00718809 2015-06-10

Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
21 enrolled 13 charts
Thoracic

Thymoma

NCT01267266 2015-04-01

Saracatinib in Treating Patients With Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
31 enrolled 6 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡